Literature DB >> 27091646

Depression and Anxiety During Pregnancy: Evaluating the Literature in Support of Clinical Risk-Benefit Decision-Making.

Katharine Baratz Dalke1,2, Amy Wenzel3, Deborah R Kim3.   

Abstract

Depression and anxiety during pregnancy are common, and patients and providers are faced with complex decisions regarding various treatment modalities. A structured discussion of the risks and benefits of options with the patient and her support team is recommended to facilitate the decision-making process. This clinically focused review, with emphasis on the last 3 years of published study data, evaluates the major risk categories of medication treatments, namely pregnancy loss, physical malformations, growth impairment, behavioral teratogenicity, and neonatal toxicity. Nonpharmacological treatment options, including neuromodulation and psychotherapy, are also briefly reviewed. Specific recommendations, drawn from the literature and the authors' clinical experience, are also offered to help guide the clinician in decision-making.

Entities:  

Keywords:  Anxiety; Decision-making; Depression; Informed consent; Pharmacotherapy; Pregnancy

Mesh:

Year:  2016        PMID: 27091646     DOI: 10.1007/s11920-016-0698-x

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  119 in total

1.  Antidepressant drugs during pregnancy and infant congenital heart defect.

Authors:  Bengt Källén; Petra Otterblad Olausson
Journal:  Reprod Toxicol       Date:  2006-01-06       Impact factor: 3.143

2.  Pregnancy outcome following maternal exposure to mirtazapine: a multicenter, prospective study.

Authors:  Ursula Winterfeld; Gil Klinger; Alice Panchaud; Sally Stephens; Judy Arnon; Heli Malm; Bernke Te Winkel; Maurizio Clementi; Alessandra Pistelli; Eva Maňáková; Georgios Eleftheriou; Paul Merlob; Yusuf C Kaplan; Thierry Buclin; Laura E Rothuizen
Journal:  J Clin Psychopharmacol       Date:  2015-06       Impact factor: 3.153

3.  Pregnant women with posttraumatic stress disorder and risk of preterm birth.

Authors:  Kimberly Ann Yonkers; Megan V Smith; Ariadna Forray; C Neill Epperson; Darce Costello; Haiqun Lin; Kathleen Belanger
Journal:  JAMA Psychiatry       Date:  2014-08       Impact factor: 21.596

Review 4.  Antidepressant use in pregnant and postpartum women.

Authors:  Kimberly A Yonkers; Katherine A Blackwell; Janis Glover; Ariadna Forray
Journal:  Annu Rev Clin Psychol       Date:  2013-12-02       Impact factor: 18.561

5.  Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.

Authors:  L R Dolovich; A Addis; J M Vaillancourt; J D Power; G Koren; T R Einarson
Journal:  BMJ       Date:  1998-09-26

6.  Relapse of major depression in women who continue or discontinue antidepressant medication during pregnancy.

Authors:  Constance Guille; C Neill Epperson
Journal:  Am J Psychiatry       Date:  2013-05       Impact factor: 18.112

7.  Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: population based cohort study and sibling design.

Authors:  Kari Furu; Helle Kieler; Bengt Haglund; Anders Engeland; Randi Selmer; Olof Stephansson; Unnur Anna Valdimarsdottir; Helga Zoega; Miia Artama; Mika Gissler; Heli Malm; Mette Nørgaard
Journal:  BMJ       Date:  2015-04-17

8.  Prescribing of antipsychotics in UK primary care: a cohort study.

Authors:  Louise Marston; Irwin Nazareth; Irene Petersen; Kate Walters; David P J Osborn
Journal:  BMJ Open       Date:  2014-12-18       Impact factor: 2.692

Review 9.  Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports.

Authors:  Jennita Reefhuis; Owen Devine; Jan M Friedman; Carol Louik; Margaret A Honein
Journal:  BMJ       Date:  2015-07-08

Review 10.  The use of psychotropic medication during pregnancy: how about the newborn?

Authors:  Noera Kieviet; Koert M Dolman; Adriaan Honig
Journal:  Neuropsychiatr Dis Treat       Date:  2013-08-28       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.